<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337440</url>
  </required_header>
  <id_info>
    <org_study_id>KanazawaU-1</org_study_id>
    <nct_id>NCT01337440</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases</brief_title>
  <official_title>The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanazawa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanazawa University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objectives

        1. To test whether Ursodeoxycholic Acid (UDCA) increases Glucagon-like peptide-1 (GLP-1)
           response to nutrients and improves glycemic control in people with type 2 diabetes.

        2. To test whether sitagliptin enhances UDCA-induced beneficial effect in GLP-1 levels and
           glycemic control.

        3. To test safety of combination therapy of sitagliptin and UDCA in people with type 2
           diabetes.

      2. Clinical hypothesis.

        1. UDCA increases GLP-1 response to nutrients via provoking bile acids excretion from the
           liver to the intestine/colon.

        2. UDCA improves glycemic control in people with type 2 diabetes.

        3. Sitagliptin enhances UDCA-induced response of GLP-1 to nutrients.

        4. Sitagliptin has additive beneficial effects with UDCA in glycemic control in people with
           type 2 diabetes.

        5. Combination therapy of sitagliptin and UDCA is safe and well-tolerated in people with
           type 2 diabetes.

        6. The combination therapy may loose weight by unique mechanisms of each agent; GLP-1
           inhibits appetite by acting on CNS and gastrointestinal motility, whereas UDCA-enhanced
           circulating primary bile acids increases energy expenditure through the pathway
           involving G protein-coupled bile acid receptor 1 (Gpbar1, or M-Bar, TGR-5) and
           subsequent activation of type 2 iodothyronine deiodinase (D2) in brown adipose and
           muscle tissues, as reported previously.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA)</measure>
    <time_frame>6 months</time_frame>
    <description>the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA) treating by Ursodeoxycholic Acid (UDCA)or sitagliptin monotherapy, and combination therapy of both two drugs for 3 monthes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glucagon-like peptide-1 (GLP-1) response to lipid meal test (fat 55%)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in energy expenditure</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fasting plasma glucose level</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in autonomic nerve function</measure>
    <time_frame>6 months</time_frame>
    <description>This is performed by power-spectrum analyses of heart rate variability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>UDCA pretreatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin pretreatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UDCA</intervention_name>
    <description>Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.</description>
    <arm_group_label>Sitagliptin pretreatment</arm_group_label>
    <other_name>Ursodeoxycholic acid (UDCA) goes by the trade names Urso.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid.</description>
    <arm_group_label>UDCA pretreatment</arm_group_label>
    <other_name>Sitagliptin sold under the trade name Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes

          2. HbA1c &gt;=6.5% during 8 weeks prior to the study

          3. Treated with none or single oral hypoglycemic agent(OHA: sulfonyl ureas, biguanides,
             or thiazolidinediones) over 12 weeks prior to the study

        Exclusion Criteria:

          1. Non-Type 2 diabetes

          2. Medical history and/or complication of diabetic ketoacidosis

          3. Medical history and/or complication of severe hypoglycemia

          4. Insulin treatment within 16 weeks prior to the study

          5. Treatment with alpha-glucosidase inhibitors or sitagliptin within 12 weeks prior to
             the study

          6. Treatment with glucocorticoid

          7. Unstable glycemic control

          8. Hypersensitivity to or contraindication of sitagliptin and voglibose

          9. Aspartate transaminase (AST) or alanine transaminase (ALT) &gt;=2.5 time of institutional
             upper normal limit

         10. Uncontrolled hypertension (systolic blood pressure &gt;160mmHg or diastolic blood
             pressure &gt;100mmHg)

         11. Severe health problems not suitable for the study

         12. Pregnant or lactating women

         13. Hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toshinari Takamura, MD, PhD</last_name>
    <phone>+81-76-265-2233</phone>
    <email>ttakamura@m-kanazawa.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Internal medicine, Kanazawa university hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshinari Takamura, MD, PhD</last_name>
      <phone>+81-76-265-2233</phone>
      <email>ttakamura@m-kanazawa.jp</email>
    </contact>
    <investigator>
      <last_name>Kosuke R Shima, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, Sasaki M, Nakanuma Y, Miura K, Kaneko S. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol. 2007 Apr;42(4):312-7. Epub 2007 Apr 26.</citation>
    <PMID>17464461</PMID>
  </reference>
  <reference>
    <citation>Takamura T, Sakurai M, Nakamura M, Shimizu A, Ota T, Misu H, Takeshita Y, Tsuchiyama N, Kurita S, Ando H, Kaneko S. Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. Diabetes Res Clin Pract. 2007 Mar;75(3):278-84. Epub 2006 Oct 27.</citation>
    <PMID>17069922</PMID>
  </reference>
  <reference>
    <citation>Tsuchiyama N, Takamura T, Ando H, Sakurai M, Shimizu A, Kato K, Kurita S, Kaneko S. Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes. Diabetes Care. 2007 Oct;30(10):2583-7. Epub 2007 Jul 20.</citation>
    <PMID>17644622</PMID>
  </reference>
  <results_reference>
    <citation>Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, Kurita S, Arai K, Yamashita T, Sasaki M, Nakanuma Y, Kaneko S. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010 Feb;33(2):284-6. doi: 10.2337/dc09-0148. Epub 2009 Oct 30.</citation>
    <PMID>19880582</PMID>
  </results_reference>
  <results_reference>
    <citation>Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006 Jan 26;439(7075):484-9. Epub 2006 Jan 8.</citation>
    <PMID>16400329</PMID>
  </results_reference>
  <results_reference>
    <citation>Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007 Jul 11;298(2):194-206. Review.</citation>
    <PMID>17622601</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009 Sep;10(3):167-77. doi: 10.1016/j.cmet.2009.08.001.</citation>
    <PMID>19723493</PMID>
  </results_reference>
  <results_reference>
    <citation>Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol. 2001 Jul;35(1):134-46. Review.</citation>
    <PMID>11495032</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>BANYU TOKYO</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <keyword>Ursodeoxycholic Acid</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>bile acids</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

